Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Indication 1
Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
The use of this vaccine should be in line with official recommendations.
Coadministration:
Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines 1:
— Meningococcal groups A, C, W, Y conjugate
— Diphtheria, tetanus, acellular pertussis, inactivated polio
— Haemophilus influenzae type b
— Hepatitis B
— Heptavalent pneumococcal conjugate
— Measles, mumps, rubella
— Varicella
Storage and stability 1
- Shelf life: 3 years
- Store in a refrigerator (2°C–8°C)
- Do not freeze
- Store in the original package in order to protect from light
- Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
- Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension.
References:
- Bexsero Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/bexsero-suspension-for-injection-in-pre-filled-syringe-31445/spc Last Accessed: April 2021
- HSE Immunisation Guidelines. Available at: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf, Last Accessed: April 2021
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Bexsero is a registered trademark of the GlaxoSmithKline Group of Companies
